ASML Earnings Report Approaches Amid Market Scrutiny

ASML's Q1 2026 results, due April 15, are key to validating its annual guidance amid a massive order backlog, a major dividend hike, and recent stock weakness.

With its quarterly results due in under two weeks, ASML Holding NV finds itself at a critical juncture. The market is keenly awaiting the report to assess the company's ability to validate its cautious annual guidance against a backdrop of strong orders and recent share price weakness.

Institutional Activity and Shareholder Returns

Recent filings reveal divergent moves among major investors. Formidable Asset Management significantly increased its stake by 123.5%, while Eldred Rock Partners and Allspring Global Investments reduced their holdings by 10.1% and 12.1%, respectively. Concurrently, ASML announced a substantial increase in its quarterly cash dividend to $3.1771 per share, up from $1.88. The payment is scheduled for May 5, 2026, with an ex-dividend date of April 27.

A Robust Order Book Contrasts with Cautious Outlook

The company concluded 2025 with a formidable order backlog valued at €38.8 billion. This position was further strengthened by a recent major purchase order from SK Hynix, worth €7.97 billion for extreme ultraviolet (EUV) lithography systems, with deliveries extending into 2027. This deal underscores the persistent, structural demand for ASML's core semiconductor manufacturing technology.

Despite this solid foundation, the equity has faced selling pressure. Geopolitical uncertainties and management's guarded outlook for 2026 have weighed on investor sentiment. The stock recently declined by approximately 3% on two consecutive trading sessions. Currently, shares trade about 11% below their 52-week high.

Analyst Expectations for Q1 and Full-Year Guidance

Market experts are anticipating a strong start to the year. The consensus forecast for ASML's first-quarter 2026 revenue stands at $10.21 billion, which would represent year-over-year growth of roughly 25%. For context, the company's total revenue for the full year 2025 was €32.7 billion. Management's own net sales target for 2026 is set between €34 billion and €39 billion.

The average analyst rating for the stock is "Moderate Buy," accompanied by a consensus price target of $1,482.50.

All eyes are now on the official quarterly release scheduled for April 15. The report will be pivotal in determining whether the firm's substantial backlog and projected revenue growth can effectively counter the prevailing market skepticism surrounding its annual forecast.